Global Albumin Market Overview

The Global Albumin Market size is expected to grow from USD 5.57 billion in 2022 to USD 9.48 billion by 2030, at a CAGR of 7.9% during the forecast period (2023-2030).

Albumin is a simple protein present in both, animal and plant physiological fluids and tissues. In humans, it is synthesized in the liver and accounts for 25% of the total proteins synthesized by the liver. After synthesis in the liver, it is released into the bloodstream. It plays many vital roles such as maintenance of appropriate osmotic pressure, binding & transport of various compounds like hormones & drugs in blood, and neutralization of free radicals. Albumin is an important binding protein of plasma constituents that if circulated in free-form would be toxic to human health. It also supplies amino acids when hydrolyzed, and is the main extravascular scavenger. In the human blood albumin is the most abundant found circulating protein. The most important role of albumin is the transportation of both endogenous and exogenous compounds. This property of albumin facilitates the transport of hydrophobic molecules such as long-chain fatty acids as well as a variety of other blood components such as bilirubin, metal ions such as zinc and copper, and drugs such as ibuprofen and warfarin. The growing awareness about the advantages of albumin among pharma and biotechnology industries is stimulating the development of the albumin market throughout the forecast period.

Market Dynamics and Key Factors in Albumin:

Drivers:

Albumin plays an important role in the transportation of serval vital components present in the blood. This characteristic of albumin can be modified for the transportation of vital drugs to the target organs. With the advancement in DNA technology and the growing popularity of recombinant DNA technology, recombinant albumin can be prepared in the laboratory. This recombinant albumin can be utilized in the treatment of hypovolemia, hypoalbuminemia, and others. Moreover, albumin can act as a carrier for various drugs, and this characteristic of albumin can be utilized for the transportation of cancer drugs to the tumor localized region of the body, and it also promotes the accumulation of the drug within tumors. With the increasing number of individuals suffering from cancer, this application of albumin can be utilized to treat the root cause of cancer. A low level of albumin can affect the drug distribution of several drugs and other biological compounds.

Both acute and chronic disorders of the liver led to hypoalbuminemia, edema, and many other disturbances. For more than 50 years, albumin preparations generated by separating human plasma have been used in therapeutic uses to treat hypoalbuminemia and abnormal drug transport. Hypoalbuminemia is a condition due to deficiency of albumin in the blood. It causes swelling that is present all over the body or swelling in one part of the body. One may even have muscle weakness, fatigue, or cramps. Hypoalbuminemia can be treated with the dosage of albumin. It also plays a vital role in maintaining blood volume. Furthermore, the rise in the number of patients suffering from the liver disorder is further propelling the growth of the market over the forecast period.

Restraints:

Stringent government regulations over the manufacturing of therapeutic drugs and the lower availability of therapeutic products are the main factors hampering the expansion of the albumin market in the projected timeframe. The lack of equipment required for the storage and separation of albumin in developing countries and the high prices of the albumin is the major factors hindering the development of the market in the projected period. 

Opportunities:

The rise in the number of individuals suffering from liver disorders has gradually increased over the past few years. Synthesis of albumin takes place in the liver and any liver-related disease may affect the production of the albumin. According to CDC, an estimated 42,230 individuals in the United States will get diagnosed with primary liver cancer in 2021 and approximately 30,230 deaths may occur due to it. In addition, liver cancer is the sixth most common type of cancer found in the population. Cancer and other liver-related disorder severely affect the production of serum albumin. This lack of production can be overcome by administering albumin externally thus, creating a profitable opportunity for the market players to develop albumin that can be safely given to individuals without causing any allergies.

Market Segmentation For Albumin

Depending on the product, the recombinant albumin segment is predicted to have the highest share of the market in the analysis period. The usage of recombinant albumin can effectively cut costs down the line by enhancing safety, and recombinant albumin tends to offer greater yields and reduced batch-to-batch variability during processing, resulting in smoother and faster development. If albumin is used early in the development cycle, it can effectively solve stability issues thus, resolving delayed product launches. For vaccine products, the inclusion of recombinant human albumin can enhance the stability in both liquid and solid-state, as well as improve yields during harvesting and processing of viruses for vaccine preparation. Moreover, recombinant albumin eliminates the host-derived proteases and the presence of pathogens. In addition, recombinant albumin ensures high purity, and high thiol-free content thus, the demand for recombinant albumin is expected to rise in the forecasted timeframe.   

Depending on applications, the therapeutics & drug delivery segment is expected to dominate the albumin market over the forecast period. Albumin binds a wide range of substances, in particular lipid-soluble anions. With a typical level of 1–2 molecules per molecule of albumin, the majority of circulating long-chain fatty acids in plasma is albumin coupled to a hydrophobic site. Bilirubin and medicines including salicylate, warfarin, phenylbutazone, and clofibrate bind to the same two locations. Because only the free drug is active, they may displace each other, resulting in hazardous increases in drug activity. Serum albumin, a naturally occurring ligand carrier that is highly concentrated and circulates for a long time in the blood, has shown great potential as an anti-cancer drug carrier. Albumin can extend the circulation half-life of medications that would otherwise be removed quickly and, more significantly, enhance their accumulation within tumors.

Depending on end-users, the pharmaceutical and biotechnology industry segment is forecasted to lead the albumin market in the forecast period. To provide individuals with the required dosage of albumin many pharmaceutical companies have started the manufacturing of human albumin. The biotechnology sector mostly utilizes serum albumin for the growth of cultures. After the culture gets mature, necessary secondary metabolites secreted by the grown culture are extracted and then is utilized for the treatment of various diseases. Moreover, human serum albumin has the longest half-life, good biocompatibility, and low immunogenicity as compared to the other proteins, which can be employed by pharma companies to develop drugs that can be transferred with the help of albumin to the targeted tumor. The increasing number of cancer patients is stimulating the expansion of this segment.

Players Covered in Albumin market are :

• Albumedix Ltd. (UK)
• Albumin Bioscience (US)
• Biotest AG (Germany)
• CSL Behring (US)
• Grifols International SA (Spain)
• HiMedia Laboratories Pvt. Ltd. (India)
• InVitria (US)
• Medxbio Pte. Ltd. (Singapore)
• MilliporeSigma (US)
• Octapharma AG (Switzerland)
• RayBiotech Inc. (Georgia)
• Seracare Life Sciences Inc. (the US)
• Akron Biotech (US)
• Bristol-Myers Squibb Company (US)

Regional Analysis of Albumin Market:

The North American region is forecasted to dominate the albumin market attributed to the rise in the number of people suffering from liver disorders. According to National Survey on Drug Use and Health (NSDUH) in 2019, among 86,688 liver disease-related deaths, 43.1% were due to alcohol use disorder. It also puts a burden on the economy, as US$ 249 billion were spent on alcohol-related health problems in the USA. More people are getting used to alcohol drinking in this region which has fueled the demand for external dosage of albumin. Moreover, the presence of prominent companies involved in the production of albumin is supporting the growth of the market in this region.

The European region is anticipated to have the second-highest share of the albumin market over the analysis period. The usage of albumin to manufacture vaccines and to deliver drugs in particular health conditions are the vital functions for which the manufacturing companies in this region are leveraging the usage of albumin. Albumin plays a vital role in the manufacturing of vaccines. It increases the viral yield and thus, lowers the overall production cost. Lower production cost improves the distribution of vaccines as high vaccine cost could limit the spread of the vaccinations. Moreover, research institutes in this region are experimenting with novel drug transportation methods to increase the efficacy of the drug thus, promoting the development of the albumin market in this region.

The albumin market in the Asia-Pacific region is expected to develop at the highest CAGR during the forecast period. The rise of the biotechnology sector in this region is the main factor propelling the market growth in this region. Furthermore, the growing investments from foreign companies and the supportive government policies are further strengthening the expansion of the albumin market in this region. With the two most populous countries-India, and China in this region, the rate of people suffering from liver disorders is high, which provides favorable conditions for the development of the albumin market.

Recent Developments in Albumin Market:

• In November 2021, Grifols, a leading global producer of plasma-derived medicines, announced the launch of its latest albumin portfolio innovation, ALBUTEIN FlexBag™ (Albumin [Human] U.S.P.) in 5% and 25% concentrations.
• In March 2021, Albumedix Ltd, the chief company that manufactures recombinant human albumin announced that it has partnered with FUJIFILM Wako Pure Chemical Corporation to supply human albumin for Chinese and Japanese markets.
• In February 2021, Albumedix Ltd, the chief company that manufactures recombinant human albumin announced that it has collaborated with Cell and Gene Therapy Catapult (CGT Catapult), to investigate the usage of Albumedix´ proprietary albumin-based solutions for advanced therapy applications, including viral vectors manufacturing.

COVID-19 Impact on Albumin Market:

The outbreak of COVID-19 severely impacted the manufacturing facilities of several industries. To curb the spread of the SARS CoV-2 virus, the nationwide lockdown was imposed by multiple nations across the globe. There was a shortage of albumin products in the market due to the unavailability of the workforce and restrictions on transport. Studies found that a low level of albumin increased the mortality rate in individuals. Therefore, the demand for external albumin dosage significantly increased during the pandemic period. The pandemic disclosed the fragile supply chains present in the albumin as well as in other medical products. China and India are the two major suppliers of raw active pharmaceutical ingredients (APIs). The rapid spread of the virus in these countries halted the export of APIs to other countries. The United States Food and Drug Administration (FDA) and American Society of Health-System Pharmacists (ASHP), published a "drug shortage list" during the pandemic period consisting of potential COVID-19 treatments and intensive care unit (ICU) medications for COVID-19 patients. To summarize, the demand for albumin is expected to rise in the post-pandemic period attributed to the growing number of liver-related disorders.

Chapter 1: Introduction
 1.1 Research Objectives
 1.2 Research Methodology
 1.3 Research Process
 1.4 Scope and Coverage
  1.4.1 Market Definition
  1.4.2 Key Questions Answered
 1.5 Market Segmentation

Chapter 2:Executive Summary

Chapter 3:Growth Opportunities By Segment
 3.1 By Product
 3.2 By Application
 3.3 By End-Users

Chapter 4: Market Landscape
 4.1 Porter's Five Forces Analysis
  4.1.1 Bargaining Power of Supplier
  4.1.2 Threat of New Entrants
  4.1.3 Threat of Substitutes
  4.1.4 Competitive Rivalry
  4.1.5 Bargaining Power Among Buyers
 4.2 Industry Value Chain Analysis
 4.3 Market Dynamics
  4.3.1 Drivers
  4.3.2 Restraints
  4.3.3 Opportunities
  4.5.4 Challenges
 4.4 Pestle Analysis
 4.5 Technological Roadmap
 4.6 Regulatory Landscape
 4.7 SWOT Analysis
 4.8 Price Trend Analysis
 4.9 Patent Analysis
 4.10 Analysis of the Impact of Covid-19
  4.10.1 Impact on the Overall Market
  4.10.2 Impact on the Supply Chain
  4.10.3 Impact on the Key Manufacturers
  4.10.4 Impact on the Pricing

Chapter 5: Albumin Market by Product
 5.1 Albumin Market Overview Snapshot and Growth Engine
 5.2 Albumin Market Overview
 5.3 Recombinant Albumin
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size (2016-2028F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Recombinant Albumin: Grographic Segmentation
 5.4 Bovine Serum Albumin
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size (2016-2028F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Bovine Serum Albumin: Grographic Segmentation
 5.5 Human Serum Albumin
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size (2016-2028F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Human Serum Albumin: Grographic Segmentation

Chapter 6: Albumin Market by Application
 6.1 Albumin Market Overview Snapshot and Growth Engine
 6.2 Albumin Market Overview
 6.3 Ingredient in Culture Media
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size (2016-2028F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Ingredient in Culture Media: Grographic Segmentation
 6.4 Vaccine Ingredient
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size (2016-2028F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Vaccine Ingredient: Grographic Segmentation
 6.5 Therapeutics & Drug Delivery
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size (2016-2028F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Therapeutics & Drug Delivery: Grographic Segmentation
 6.6 Others
  6.6.1 Introduction and Market Overview
  6.6.2 Historic and Forecasted Market Size (2016-2028F)
  6.6.3 Key Market Trends, Growth Factors and Opportunities
  6.6.4 Others: Grographic Segmentation

Chapter 7: Albumin Market by End-Users
 7.1 Albumin Market Overview Snapshot and Growth Engine
 7.2 Albumin Market Overview
 7.3 Research Institutes
  7.3.1 Introduction and Market Overview
  7.3.2 Historic and Forecasted Market Size (2016-2028F)
  7.3.3 Key Market Trends, Growth Factors and Opportunities
  7.3.4 Research Institutes: Grographic Segmentation
 7.4 Pharmaceutical
  7.4.1 Introduction and Market Overview
  7.4.2 Historic and Forecasted Market Size (2016-2028F)
  7.4.3 Key Market Trends, Growth Factors and Opportunities
  7.4.4 Pharmaceutical: Grographic Segmentation
 7.5 Biotechnology Industry
  7.5.1 Introduction and Market Overview
  7.5.2 Historic and Forecasted Market Size (2016-2028F)
  7.5.3 Key Market Trends, Growth Factors and Opportunities
  7.5.4 Biotechnology Industry: Grographic Segmentation

Chapter 8: Company Profiles and Competitive Analysis
 8.1 Competitive Landscape
  8.1.1 Competitive Positioning
  8.1.2 Albumin Sales and Market Share By Players
  8.1.3 Industry BCG Matrix
  8.1.4 Ansoff Matrix
  8.1.5 Albumin Industry Concentration Ratio (CR5 and HHI)
  8.1.6 Top 5 Albumin Players Market Share
  8.1.7 Mergers and Acquisitions
  8.1.8 Business Strategies By Top Players
 8.2 ALBUMEDIX LTD.
  8.2.1 Company Overview
  8.2.2 Key Executives
  8.2.3 Company Snapshot
  8.2.4 Operating Business Segments
  8.2.5 Product Portfolio
  8.2.6 Business Performance
  8.2.7 Key Strategic Moves and Recent Developments
  8.2.8 SWOT Analysis
 8.3 ALBUMIN BIOSCIENCE
 8.4 BIOTEST AG
 8.5 CSL BEHRING
 8.6 GRIFOLS INTERNATIONAL SA
 8.7 HIMEDIA LABORATORIES PVT. LTD.
 8.8 INVITRIA
 8.9 MEDXBIO PTE. LTD.
 8.10 MILLIPORESIGMA
 8.11 OCTAPHARMA AG
 8.12 RAYBIOTECH INC.
 8.13 SERACARE LIFE SCIENCES INC.
 8.14 AKRON BIOTECH
 8.15 BRISTOL-MYERS SQUIBB COMPANY
 8.16 OTHER MAJOR PLAYERS

Chapter 9: Global Albumin Market Analysis, Insights and Forecast, 2016-2028
 9.1 Market Overview
 9.2 Historic and Forecasted Market Size By Product
  9.2.1 Recombinant Albumin
  9.2.2 Bovine Serum Albumin
  9.2.3 Human Serum Albumin
 9.3 Historic and Forecasted Market Size By Application
  9.3.1 Ingredient in Culture Media
  9.3.2 Vaccine Ingredient
  9.3.3 Therapeutics & Drug Delivery
  9.3.4 Others
 9.4 Historic and Forecasted Market Size By End-Users
  9.4.1 Research Institutes
  9.4.2 Pharmaceutical
  9.4.3 Biotechnology Industry

Chapter 10: North America Albumin Market Analysis, Insights and Forecast, 2016-2028
 10.1 Key Market Trends, Growth Factors and Opportunities
 10.2 Impact of Covid-19
 10.3 Key Players
 10.4 Key Market Trends, Growth Factors and Opportunities
 10.4 Historic and Forecasted Market Size By Product
  10.4.1 Recombinant Albumin
  10.4.2 Bovine Serum Albumin
  10.4.3 Human Serum Albumin
 10.5 Historic and Forecasted Market Size By Application
  10.5.1 Ingredient in Culture Media
  10.5.2 Vaccine Ingredient
  10.5.3 Therapeutics & Drug Delivery
  10.5.4 Others
 10.6 Historic and Forecasted Market Size By End-Users
  10.6.1 Research Institutes
  10.6.2 Pharmaceutical
  10.6.3 Biotechnology Industry
 10.7 Historic and Forecast Market Size by Country
  10.7.1 U.S.
  10.7.2 Canada
  10.7.3 Mexico

Chapter 11: Europe Albumin Market Analysis, Insights and Forecast, 2016-2028
 11.1 Key Market Trends, Growth Factors and Opportunities
 11.2 Impact of Covid-19
 11.3 Key Players
 11.4 Key Market Trends, Growth Factors and Opportunities
 11.4 Historic and Forecasted Market Size By Product
  11.4.1 Recombinant Albumin
  11.4.2 Bovine Serum Albumin
  11.4.3 Human Serum Albumin
 11.5 Historic and Forecasted Market Size By Application
  11.5.1 Ingredient in Culture Media
  11.5.2 Vaccine Ingredient
  11.5.3 Therapeutics & Drug Delivery
  11.5.4 Others
 11.6 Historic and Forecasted Market Size By End-Users
  11.6.1 Research Institutes
  11.6.2 Pharmaceutical
  11.6.3 Biotechnology Industry
 11.7 Historic and Forecast Market Size by Country
  11.7.1 Germany
  11.7.2 U.K.
  11.7.3 France
  11.7.4 Italy
  11.7.5 Russia
  11.7.6 Spain
  11.7.7 Rest of Europe

Chapter 12: Asia-Pacific Albumin Market Analysis, Insights and Forecast, 2016-2028
 12.1 Key Market Trends, Growth Factors and Opportunities
 12.2 Impact of Covid-19
 12.3 Key Players
 12.4 Key Market Trends, Growth Factors and Opportunities
 12.4 Historic and Forecasted Market Size By Product
  12.4.1 Recombinant Albumin
  12.4.2 Bovine Serum Albumin
  12.4.3 Human Serum Albumin
 12.5 Historic and Forecasted Market Size By Application
  12.5.1 Ingredient in Culture Media
  12.5.2 Vaccine Ingredient
  12.5.3 Therapeutics & Drug Delivery
  12.5.4 Others
 12.6 Historic and Forecasted Market Size By End-Users
  12.6.1 Research Institutes
  12.6.2 Pharmaceutical
  12.6.3 Biotechnology Industry
 12.7 Historic and Forecast Market Size by Country
  12.7.1 China
  12.7.2 India
  12.7.3 Japan
  12.7.4 Singapore
  12.7.5 Australia
  12.7.6 New Zealand
  12.7.7 Rest of APAC

Chapter 13: Middle East & Africa Albumin Market Analysis, Insights and Forecast, 2016-2028
 13.1 Key Market Trends, Growth Factors and Opportunities
 13.2 Impact of Covid-19
 13.3 Key Players
 13.4 Key Market Trends, Growth Factors and Opportunities
 13.4 Historic and Forecasted Market Size By Product
  13.4.1 Recombinant Albumin
  13.4.2 Bovine Serum Albumin
  13.4.3 Human Serum Albumin
 13.5 Historic and Forecasted Market Size By Application
  13.5.1 Ingredient in Culture Media
  13.5.2 Vaccine Ingredient
  13.5.3 Therapeutics & Drug Delivery
  13.5.4 Others
 13.6 Historic and Forecasted Market Size By End-Users
  13.6.1 Research Institutes
  13.6.2 Pharmaceutical
  13.6.3 Biotechnology Industry
 13.7 Historic and Forecast Market Size by Country
  13.7.1 Turkey
  13.7.2 Saudi Arabia
  13.7.3 Iran
  13.7.4 UAE
  13.7.5 Africa
  13.7.6 Rest of MEA

Chapter 14: South America Albumin Market Analysis, Insights and Forecast, 2016-2028
 14.1 Key Market Trends, Growth Factors and Opportunities
 14.2 Impact of Covid-19
 14.3 Key Players
 14.4 Key Market Trends, Growth Factors and Opportunities
 14.4 Historic and Forecasted Market Size By Product
  14.4.1 Recombinant Albumin
  14.4.2 Bovine Serum Albumin
  14.4.3 Human Serum Albumin
 14.5 Historic and Forecasted Market Size By Application
  14.5.1 Ingredient in Culture Media
  14.5.2 Vaccine Ingredient
  14.5.3 Therapeutics & Drug Delivery
  14.5.4 Others
 14.6 Historic and Forecasted Market Size By End-Users
  14.6.1 Research Institutes
  14.6.2 Pharmaceutical
  14.6.3 Biotechnology Industry
 14.7 Historic and Forecast Market Size by Country
  14.7.1 Brazil
  14.7.2 Argentina
  14.7.3 Rest of SA

Chapter 15 Investment Analysis

Chapter 16 Analyst Viewpoint and Conclusion

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. ALBUMIN MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. ALBUMIN MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. ALBUMIN MARKET COMPETITIVE RIVALRY
TABLE 005. ALBUMIN MARKET THREAT OF NEW ENTRANTS
TABLE 006. ALBUMIN MARKET THREAT OF SUBSTITUTES
TABLE 007. ALBUMIN MARKET BY PRODUCT
TABLE 008. RECOMBINANT ALBUMIN MARKET OVERVIEW (2016-2028)
TABLE 009. BOVINE SERUM ALBUMIN MARKET OVERVIEW (2016-2028)
TABLE 010. HUMAN SERUM ALBUMIN MARKET OVERVIEW (2016-2028)
TABLE 011. ALBUMIN MARKET BY APPLICATION
TABLE 012. INGREDIENT IN CULTURE MEDIA MARKET OVERVIEW (2016-2028)
TABLE 013. VACCINE INGREDIENT MARKET OVERVIEW (2016-2028)
TABLE 014. THERAPEUTICS & DRUG DELIVERY MARKET OVERVIEW (2016-2028)
TABLE 015. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 016. ALBUMIN MARKET BY END-USERS
TABLE 017. RESEARCH INSTITUTES MARKET OVERVIEW (2016-2028)
TABLE 018. PHARMACEUTICAL MARKET OVERVIEW (2016-2028)
TABLE 019. BIOTECHNOLOGY INDUSTRY MARKET OVERVIEW (2016-2028)
TABLE 020. NORTH AMERICA ALBUMIN MARKET, BY PRODUCT (2016-2028)
TABLE 021. NORTH AMERICA ALBUMIN MARKET, BY APPLICATION (2016-2028)
TABLE 022. NORTH AMERICA ALBUMIN MARKET, BY END-USERS (2016-2028)
TABLE 023. N ALBUMIN MARKET, BY COUNTRY (2016-2028)
TABLE 024. EUROPE ALBUMIN MARKET, BY PRODUCT (2016-2028)
TABLE 025. EUROPE ALBUMIN MARKET, BY APPLICATION (2016-2028)
TABLE 026. EUROPE ALBUMIN MARKET, BY END-USERS (2016-2028)
TABLE 027. ALBUMIN MARKET, BY COUNTRY (2016-2028)
TABLE 028. ASIA PACIFIC ALBUMIN MARKET, BY PRODUCT (2016-2028)
TABLE 029. ASIA PACIFIC ALBUMIN MARKET, BY APPLICATION (2016-2028)
TABLE 030. ASIA PACIFIC ALBUMIN MARKET, BY END-USERS (2016-2028)
TABLE 031. ALBUMIN MARKET, BY COUNTRY (2016-2028)
TABLE 032. MIDDLE EAST & AFRICA ALBUMIN MARKET, BY PRODUCT (2016-2028)
TABLE 033. MIDDLE EAST & AFRICA ALBUMIN MARKET, BY APPLICATION (2016-2028)
TABLE 034. MIDDLE EAST & AFRICA ALBUMIN MARKET, BY END-USERS (2016-2028)
TABLE 035. ALBUMIN MARKET, BY COUNTRY (2016-2028)
TABLE 036. SOUTH AMERICA ALBUMIN MARKET, BY PRODUCT (2016-2028)
TABLE 037. SOUTH AMERICA ALBUMIN MARKET, BY APPLICATION (2016-2028)
TABLE 038. SOUTH AMERICA ALBUMIN MARKET, BY END-USERS (2016-2028)
TABLE 039. ALBUMIN MARKET, BY COUNTRY (2016-2028)
TABLE 040. ALBUMEDIX LTD.: SNAPSHOT
TABLE 041. ALBUMEDIX LTD.: BUSINESS PERFORMANCE
TABLE 042. ALBUMEDIX LTD.: PRODUCT PORTFOLIO
TABLE 043. ALBUMEDIX LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 043. ALBUMIN BIOSCIENCE: SNAPSHOT
TABLE 044. ALBUMIN BIOSCIENCE: BUSINESS PERFORMANCE
TABLE 045. ALBUMIN BIOSCIENCE: PRODUCT PORTFOLIO
TABLE 046. ALBUMIN BIOSCIENCE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 046. BIOTEST AG: SNAPSHOT
TABLE 047. BIOTEST AG: BUSINESS PERFORMANCE
TABLE 048. BIOTEST AG: PRODUCT PORTFOLIO
TABLE 049. BIOTEST AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 049. CSL BEHRING: SNAPSHOT
TABLE 050. CSL BEHRING: BUSINESS PERFORMANCE
TABLE 051. CSL BEHRING: PRODUCT PORTFOLIO
TABLE 052. CSL BEHRING: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 052. GRIFOLS INTERNATIONAL SA: SNAPSHOT
TABLE 053. GRIFOLS INTERNATIONAL SA: BUSINESS PERFORMANCE
TABLE 054. GRIFOLS INTERNATIONAL SA: PRODUCT PORTFOLIO
TABLE 055. GRIFOLS INTERNATIONAL SA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 055. HIMEDIA LABORATORIES PVT. LTD.: SNAPSHOT
TABLE 056. HIMEDIA LABORATORIES PVT. LTD.: BUSINESS PERFORMANCE
TABLE 057. HIMEDIA LABORATORIES PVT. LTD.: PRODUCT PORTFOLIO
TABLE 058. HIMEDIA LABORATORIES PVT. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 058. INVITRIA: SNAPSHOT
TABLE 059. INVITRIA: BUSINESS PERFORMANCE
TABLE 060. INVITRIA: PRODUCT PORTFOLIO
TABLE 061. INVITRIA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 061. MEDXBIO PTE. LTD.: SNAPSHOT
TABLE 062. MEDXBIO PTE. LTD.: BUSINESS PERFORMANCE
TABLE 063. MEDXBIO PTE. LTD.: PRODUCT PORTFOLIO
TABLE 064. MEDXBIO PTE. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 064. MILLIPORESIGMA: SNAPSHOT
TABLE 065. MILLIPORESIGMA: BUSINESS PERFORMANCE
TABLE 066. MILLIPORESIGMA: PRODUCT PORTFOLIO
TABLE 067. MILLIPORESIGMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 067. OCTAPHARMA AG: SNAPSHOT
TABLE 068. OCTAPHARMA AG: BUSINESS PERFORMANCE
TABLE 069. OCTAPHARMA AG: PRODUCT PORTFOLIO
TABLE 070. OCTAPHARMA AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 070. RAYBIOTECH INC.: SNAPSHOT
TABLE 071. RAYBIOTECH INC.: BUSINESS PERFORMANCE
TABLE 072. RAYBIOTECH INC.: PRODUCT PORTFOLIO
TABLE 073. RAYBIOTECH INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 073. SERACARE LIFE SCIENCES INC.: SNAPSHOT
TABLE 074. SERACARE LIFE SCIENCES INC.: BUSINESS PERFORMANCE
TABLE 075. SERACARE LIFE SCIENCES INC.: PRODUCT PORTFOLIO
TABLE 076. SERACARE LIFE SCIENCES INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 076. AKRON BIOTECH: SNAPSHOT
TABLE 077. AKRON BIOTECH: BUSINESS PERFORMANCE
TABLE 078. AKRON BIOTECH: PRODUCT PORTFOLIO
TABLE 079. AKRON BIOTECH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 079. BRISTOL-MYERS SQUIBB COMPANY: SNAPSHOT
TABLE 080. BRISTOL-MYERS SQUIBB COMPANY: BUSINESS PERFORMANCE
TABLE 081. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
TABLE 082. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 082. OTHER MAJOR PLAYERS: SNAPSHOT
TABLE 083. OTHER MAJOR PLAYERS: BUSINESS PERFORMANCE
TABLE 084. OTHER MAJOR PLAYERS: PRODUCT PORTFOLIO
TABLE 085. OTHER MAJOR PLAYERS: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. ALBUMIN MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. ALBUMIN MARKET OVERVIEW BY PRODUCT
FIGURE 012. RECOMBINANT ALBUMIN MARKET OVERVIEW (2016-2028)
FIGURE 013. BOVINE SERUM ALBUMIN MARKET OVERVIEW (2016-2028)
FIGURE 014. HUMAN SERUM ALBUMIN MARKET OVERVIEW (2016-2028)
FIGURE 015. ALBUMIN MARKET OVERVIEW BY APPLICATION
FIGURE 016. INGREDIENT IN CULTURE MEDIA MARKET OVERVIEW (2016-2028)
FIGURE 017. VACCINE INGREDIENT MARKET OVERVIEW (2016-2028)
FIGURE 018. THERAPEUTICS & DRUG DELIVERY MARKET OVERVIEW (2016-2028)
FIGURE 019. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 020. ALBUMIN MARKET OVERVIEW BY END-USERS
FIGURE 021. RESEARCH INSTITUTES MARKET OVERVIEW (2016-2028)
FIGURE 022. PHARMACEUTICAL MARKET OVERVIEW (2016-2028)
FIGURE 023. BIOTECHNOLOGY INDUSTRY MARKET OVERVIEW (2016-2028)
FIGURE 024. NORTH AMERICA ALBUMIN MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 025. EUROPE ALBUMIN MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 026. ASIA PACIFIC ALBUMIN MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 027. MIDDLE EAST & AFRICA ALBUMIN MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 028. SOUTH AMERICA ALBUMIN MARKET OVERVIEW BY COUNTRY (2016-2028)